DIRS.INFO The most relevant business & tech news

☆ The most expensive drug in the world has a $3.5 million price tag. 2 potential patients share their hopes and fears for the one-time treatment.
▼ + stars: | 2022-12-05 | by ( Andrew Dunn | ) www.businessinsider.com time to read: +7 min

The FDA has approved a new gene therapy to treat hemophilia B, a genetic bleeding disorder. The drugmaker CSL Behring set a $3.5 million price for the one-time treatment. Lackey is learning to live with a severe case of hemophilia B, a rare genetic condition that keeps blood from clotting properly. But a critical unknown in judging CSL's $3.5 million price is the durability of the treatment. Lojewski said the $3.5 million price wasn't guided by other gene-therapy prices.

☆ The most expensive drug in the world just got approved at $3.5 million, and hemophilia patients are conflicted: 'Compared to what we pay, it doesn't seem too terrible.'
▼ + stars: | 2022-12-01 | by ( Andrew Dunn | ) www.businessinsider.com time to read: +7 min

The FDA has approved a new gene therapy to treat hemophilia B, a genetic bleeding disorder. Hemophilia patients told Insider they're excited about the new drug but worried about the price. Lackey is learning to live with a severe case of hemophilia B, a rare genetic condition that keeps blood from clotting properly. While the treatment breaks ground as the first approved gene therapy for hemophilia, its price is also unprecedented. Lojewski said the $3.5 million price wasn't guided by other gene-therapy prices.

☆ Outperforming asset manager picks the stocks set to win as margins get squeezed
▼ + stars: | 2022-11-25 | by ( Zavier Ong | ) www.cnbc.com time to read: +3 min

"Consumers are going to have their purse strings pulled by utility bills, higher mortgage costs, higher petrol prices, and there's going to be margin squeeze." He said wage pressure and higher commodity prices were particularly challenging and could eat into companies' margins. Luxury Luxury stocks are another favorite for Armstrong. Moreover, the "massive" profit margins of luxury companies are also insulated from increases in input prices, he added. Within the space, Armstrong's fund owns French luxury goods companies LVMH and Hermes , given their "defendable margins" and the ability to be price setters.

☆ A top Wall Street analyst names 6 major events that could send biotech stocks soaring between now and the end of 2022
▼ + stars: | 2022-11-14 | by ( Yeji Jesse Lee | ) www.businessinsider.com time to read: +5 min

Cantor Fitzgerald analysts named six big events to mark on your calendar. While the majority of the expected events are set to come from smaller biotech companies, bigger companies — like Roche, Gilead, and Alnylam — have their own events coming through the pipeline. Here are the six major events from big biotech companies that could send stocks soaring:1. Cantor Fitzgerald analysts give Gilead's stock a neutral rating and they have an overweight rating on Arcus. Lenacapavir "could become a much bigger piece of the HIV growth narrative over the next few years," according to Cantor Fitzgerald analysts.

☆ Novartis to cut its Irish workforce by up to 25%
▼ + stars: | 2022-10-13 | by ( ) www.reuters.com time to read: +1 min

DUBLIN, Oct 13 (Reuters) - Novartis (NOVN.S) said on Thursday that it would cut up to 400 jobs in Ireland, or about a quarter of its workforce there, as part of a previously announced restructuring programme that will cut 8,000 jobs globally. read moreThe changes could potentially impact around 400 staff at its global service centre in Dublin, Novartis said in a statement. It currently employs 1,500 people in Ireland, including 1,000 in the Dublin operation that it said will continue to play a critical role. Register now for FREE unlimited access to Reuters.com Register"Ireland is an important location for Novartis due to its unique eco-system of highly educated, skilled and adaptable workforce which is critical in the knowledge-intensive, high-science, pharma sector," Novartis AG said. Register now for FREE unlimited access to Reuters.com RegisterReporting by Padraic Halpin; editing by Jonathan OatisOur Standards: The Thomson Reuters Trust Principles.

☆ Here's why Biogen's promising Alzheimer's drug data is also good news for Eli Lilly
▼ + stars: | 2022-09-28 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +8 min

The move helped Eli Lilly notch a fresh 52-week high Wednesday, the only stock in the S & P 500 to do so. Bottom line Biogen's topline data appears to be encouraging, suggesting the Alzheimer's drug helped slowed cognitive decline. Plus, we think Eli Lilly has more going for it overall than Biogen, making it a more attractive investment. Drug background Like Biogen's Alzheimer's drug lecanemab, Lilly's donanemab is an antibody that tries to reduce buildup on the brain of the amyloid beta protein . The Eli Lilly logo is shown on one of the company's offices in San Diego, California, September 17, 2020.

Register now for FREE unlimited access to Reuters.com RegisterSwiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein, Switzerland October 23, 2017. Register now for FREE unlimited access to Reuters.com RegisterIt ranked 10th in the U.S. market last year, the company added. Novartis also said it would focus in future on five areas for investment: cardiovascular, immunology, neuroscience, solid tumors and hematology medicine. The company last month said it planned to spin off Sandoz to sharpen its focus on its patented prescription medicines. Register now for FREE unlimited access to Reuters.com RegisterEditing by Mark Potter and Jason NeelyOur Standards: The Thomson Reuters Trust Principles.

☆ Why a top Roche scientist is leaving after 25 years to join a rising biotech startup using fungi to make new drugs
▼ + stars: | 2022-09-16 | by ( Andrew Dunn | ) www.businessinsider.com time to read: +5 min

After 25 years at the pharma giant Roche, the drug hunter Martin Stahl is leaving to join a biotech. CAMBRIDGE, Massachusetts — A longtime drug-hunting veteran is leaving one of the largest drugmakers to lead the science division at the biotech startup LifeMine Therapeutics, Insider has learned. FogPharmaThe big draw for Stahl was LifeMine's approach to discovering drugs. With its genetic-database approach, LifeMine hopes to greatly speed up how long it takes to develop fungi-derived drugs. Stahl said LifeMine's approach leaned on nature, rather than medicinal chemists, to design the drugs.

Search resuls for: "Swiss pharma"

8 mentions found